Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Fewer than half of the adolescents prescribed a selective serotonin reuptake inhibitor (SSRI) at two large Chicago pediatric ...

The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first ...

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

The National Academy of Sciences announced today the election of 120 members and 30 international members in recognition of ...

As diplomatic tensions simmer between India and Pakistan, leaders on both sides have a fresh set of allies with close ties to ...

Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of ...